Clinical Trial Detail

NCT ID NCT02664077
Title A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer (ARGO)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements no
Sponsors NSABP Foundation Inc
Indications

colon adenocarcinoma

Therapies

Regorafenib

Age Groups: adult

No variant requirements are available.